Table 2.
Canonical Pathways Significantly Enriched with EP-Modulated Genes
| Canonical Pathways (Total Number of Genes in Pathway) | Number of Genes in Each Phenotype (P) |
||
|---|---|---|---|
| Myofibroblast | Keratocyte | Both Phenotypes | |
| NRF2-mediated oxidative stress response (185) | 16 (3.0E-03) | 9 (9.3E-03) | 10 (6.8E-05) |
| Hepatic fibrosis/hepatic stellate cell activation (135) | 18 (9.3E-06) | 9 (3.7E-05) | |
| Cell Cycle: G2/M DNA damage checkpoint regulation (43) | 6 (5.3E-03) | 6 (7.4E-06) | |
| p53 signaling (89) | 11 (1.5E-03) | 6 (9.6E-04) | |
| ATM signaling (52) | 9 (3.5E-04) | 5 (5.1E-04) | |
| C21-steroid hormone metabolism (71) | 4 (8.5E-03) | ||
| Molecular mechanisms of cancer (372) | 25 (6.8E-03) | ||
| Biosynthesis of steroids (128) | 8 (2.6E-05) | ||
| Metabolism of xenobiotics by cytochrome P450 (210) | 10 (3.8E-03) | ||
| Factors promoting cardiogenesis in vertebrates (89) | 10 (2.9E-03) | ||
| Pancreatic adenocarcinoma signaling (117) | 12 (1.8E-03) | ||
| Cell cycle: G1/S checkpoint regulation (59) | 6 (3.8E-03) | ||
| Role of BRCA1 in DNA damage response (53) | 9 (3.0E-04) | ||
| Aryl hydrocarbon receptor signaling (157) | 20 (7E-05) | ||
| Phospholipid degradation (106) | 6 (8.3E-03) | ||
| 14-3-3-Mediated signaling (114) | 7 (6.6E-03) | ||
| Glutathione metabolism (98) | 5 (5.6E-03) | ||
| Glycerophospholipid metabolism (193) | 8 (5.1E-03) | ||
| Macropinocytosis signaling | 6 (2.3E-03) | ||
| Starch and sucrose metabolism (72) | 7 (8.7E-04) | ||
| RAN signaling (23) | 4, 3.0E-04) | ||
| Thyroid cancer signaling (41) | 6 (1.4E-04) | ||
| Colorectal cancer metastasis signaling (245) | 8 (8.91E-03) | ||
| Glioma signaling (112) | 5 (7.2E-03) | ||
| IL-8 signaling (187) | 8 (1.4E-03) | ||
| Role of CHK proteins in cell cycle checkpoint control (34) | 4 (8.5E-04) | ||
| Mitotic roles of polo-like kinase (62) | 7 (7.8E-06) | ||
Canonical pathways significantly enriched (P < 0.01) in the myofibroblast group contained 88 unique, characterized genes making 167 appearances, with 77 (87%) appearing in three pathways or fewer. The equivalent keratocyte data show 42 genes making 58 appearances, with 41 (98%) appearing in three pathways or fewer. Forty-four genes made 68 appearances and are shown in the “both phenotypes” column, with 40 (91%) appearing in three pathways or fewer. The aggregate data contained 163 unique genes, whereas (88 + 42 + 44) = 172 were expected from the component groups (i.e., there are nine redundancies). Redundancies among groups were due to multiple panels that may assign a given gene to more than one group. The following genes: BIRC5, COL1A1, FAS, IGF1, IGFBP5, MAF, GSR, SOD2, SQSTM1 and RRAS2 were redundant among groups. Each of these genes appears in Tables 3, 4, and 5.